Vol 71, No 2 (2020)
Original paper
Published online: 2020-01-13

open access

Page views 1776
Article views/downloads 791
Get Citation

Connect on Social Media

Connect on Social Media

The relationship between BSP mRNA expression and 25(OH)D/OPG in peripheral blood of newly diagnosed T2DM patients with different bone mass

Sitong Fan1, Zhe Wang12, Qi Li2, Liya Luo2, Yuyu Zhu2, Yan Yang1
Pubmed: 32096548
Endokrynol Pol 2020;71(2):160-167.


Introduction: The objective of the study was to detect the levels of osteoprotegerin (OPG) and 25-hydroxyvitamin D [25(OH)D], as well as the expression of bone sialoprotein (BSP) mRNA, in the peripheral blood of patients with newly diagnosed type 2 diabetes mellitus (T2DM) under different bone mass conditions, and to explore its role and significance in the development process of T2DM combined with osteoporosis (OP). Material and methods: A total of 225 patients hospitalised in the Endocrinology Department and General Department from May 2017 to May 2018 were enrolled and categorised into five groups: the pure T2DM group (group A, 45 patients), the bone mass reduction group (group B, 45 patients), the T2DM + bone mass reduction group (group C, 45 patients), the OP group (group D, 45 patients), and the T2DM + OP group (group E, 45 patients); meanwhile, age-matched healthy subjects undergoing physical examination in our hospital were collected as the normal control group (group NC, 45 cases). Logistic regression analysis was used to analyse the influencing factors of bone mass in patients with T2DM. Results: Compared with group B, the expression levels of glycated haemoglobin (HbA1c), 25(OH)D, N-terminal propeptide of type I procollagen (PINP), fasting plasma glucose (FPG), fasting plasma insulin (FINS), high-density lipoprotein cholesterol (HDL-C), and BSP mRNA were significantly increased while OPG and b-collagen degradation products (b-CTX) were significantly decreased in group A. Conclusion: The expression of BSP mRNA and the decrease of 25(OH)D and OPG in peripheral blood may participate in the development of diabetes and osteoporosis.

Article available in PDF format

View PDF Download PDF file


  1. Riddy DM, Delerive P, Summers RJ, et al. G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus. Pharmacol Rev. 2018; 70(1): 39–67.
  2. Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017; 5(11): 898–907.
  3. Zepp M, Kovacheva M, Altankhuyag M, et al. IDK1 is a rat monoclonal antibody against hypoglycosylated bone sialoprotein with application as biomarker and therapeutic agent in breast cancer skeletal metastasis. J Pathol Clin Res. 2018; 4(1): 55–68.
  4. Daniele G, Winnier D, Mari A, et al. The potential role of the osteopontin-osteocalcin-osteoprotegerin triad in the pathogenesis of prediabetes in humans. Acta Diabetol. 2018; 55(2): 139–148.
  5. Rochette L, Meloux A, Rigal E, et al. The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases. Pharmacol Ther. 2018; 182: 115–132.
  6. Lips P, Eekhoff M, van Schoor N, et al. Vitamin D and type 2 diabetes. J Steroid Biochem Mol Biol. 2017; 173: 280–285.
  7. Norris JM, Lee HS, Frederiksen B, et al. TEDDY Study Group, TEDDY Study Group. Plasma 25-Hydroxyvitamin D Concentration and Risk of Islet Autoimmunity. Diabetes. 2018; 67(1): 146–154.
  8. Wang H, Chen W, Li D, et al. Vitamin D and Chronic Diseases. Aging Dis. 2017; 8(3): 346–353.
  9. Chinese Medical Association Osteoporosis and Bone Mineral Disease Branch. Primary osteoporosis treatment guide . Chinese J. Osteoporosis Bone Min Dis. 2017; 10: 413–443.
  10. Wright NC, Saag KG, Dawson-Hughes B, et al. The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the United States: supplementary presentation. Osteoporos Int. 2017; 28(11): 3283–3284.
  11. Hsu JY, Cheng CY, Hsu CY, et al. Type 2 diabetes mellitus severity correlates with risk of hip fracture in patients with osteoporosis. Neth J Med. 2018; 76(2): 65–71.
  12. DeShields SC, Cunningham TD, DeShields SC, et al. Comparison of osteoporosis in US adults with type 1 and type 2 diabetes mellitus. J Endocrinol Invest. 2018; 41(9): 1051–1060.
  13. Li C, Chen P, Duan X, et al. Bioavailable 25(OH)D but Not Total 25(OH)D Is an Independent Determinant for Bone Mineral Density in Chinese Postmenopausal Women. EBioMedicine. 2017; 15: 184–192.
  14. Wise SA, Phinney KW, Tai SSC, et al. Baseline Assessment of 25-Hydroxyvitamin D Assay Performance: A Vitamin D Standardization Program (VDSP) Interlaboratory Comparison Study. J AOAC Int. 2017; 100(5): 1244–1252.
  15. Mashavi M, Menaged M, Shargorodsky M, et al. Circulating osteoprotegerin in postmenopausal osteoporotic women: marker of impaired glucose regulation or impaired bone metabolism. Menopause. 2017; 24(11): 1264–1268.
  16. Chen C, Zheng H, Qi S, et al. Genistein and Silicon Synergistically Protects Against Ovariectomy-Induced Bone Loss Through Upregulating OPG/RANKL Ratio. Biol Trace Elem Res. 2019; 188(2): 441–450.
  17. Mamolini E, Cervellati C, Greco P, et al. VDR, RANKL and OPG polymorphisms as possible predisposing cofactors of postmenopausal osteoporosis: explorative study in Italian population. Gynecol Endocrinol. 2017; 33(12): 937–941.
  18. Yan J, Liu HJ, Guo WC, et al. Low serum concentrations of Irisin are associated with increased risk of hip fracture in Chinese older women. Joint Bone Spine. 2018; 85(3): 353–358.
  19. Reginster JY, Sarkar S, Zegels B, et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone. 2004; 34(2): 344–351.
  20. Yao W, Li X, Zhao B, et al. Combined effect of TNF-α and cyclic stretching on gene and protein expression associated with mineral metabolism in cementoblasts. Arch Oral Biol. 2017; 73: 88–93.